Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction

Cardiovascular Drugs and Therapy

Volumn 13, Issue 2, 1999, Pages 127-135

  Herlitz, Johan ^a   Dellborg, Mikael ^a   Karlson, Björn W ^a   Lindqvist, Jonny ^a   Sandèn, Wanja ^a   Svensson, Helena ^a   Sjölin, Margareta ^a   Wedel, Hans ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

Acute myocardial infarction; Beta blockade; Metoprolol; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG RELEASE; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTPATIENT; PRIORITY JOURNAL; PROGNOSIS; SUDDEN DEATH; SWEDEN;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTHROPOMETRY; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; MALE; MEDICAL HISTORY TAKING; METOPROLOL; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RISK FACTORS; SMOKING;

EID: 0032930518     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007736226093     Document Type: Article

References (23)

1. 1. Norwegian, Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
2. 2. β-Blocker Heart Attack Study Group. The β-blocker heart attack trial preliminary report. JAMA 1981;46:2073-2074.
3. 3. Hjalmarson Å, Herlitz J, Malek I, et al. Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomized trial. Lancet 1981;2:823-827.
4. 4. β-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247, No. 12.
5. 5. Wikstrand J, Kendall M. The role of beta receptor blockade in preventing sudden death. Eur Heart J 1992;13:111-120.
6. 6. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with β-blockers: Importance of ancillary properties. Progr Cardiovasc Dis 1997:39:445-456.
7. 7. Dimenäs E, Kerr D, Macdonald I. Beta-adrenoceptor blockade and CNS-related subjective Symptoms: A randomized, double-blind, placebo-controlled comparison of metoprolol CR/ZOK, atenolol and propranolol LA in healthy subjects. J Clin Pharmacol 1990;30:S103-S107.
8. 8. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in mortality: Pooled results from five double-blind randomized trials. Eur Heart J 1992;13:28-32.
9. 9. Agewall S, Kendall M. Treatment with β-blockers - the value of an even plasma concentration over 24 h. J Clin Pharma Ther 1997;22:171-179.
10. 10. Sandberg A, Ragnarsson G, Johnsson UE, Sjögren J. Design of a new multiple-unit controlled-release formulation of metoprolol - Metoprolol CR. Eur J Clin Pharmacol 1988;33 (Suppl.):S3-S7.
11. 11. Blomqvist I, Westergren G, Sandberg A, Johnsson UE, Lundborg P. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: A comparison with atenolol. Eur J Clin Pharmacol 1988;33(Suppl.):S19-S24.
12. 12. Löfdhal C-G, Dahlöf C, Westergren G, Olofsson B, Svedmyr N. Controlled-release metoprolol compared with atenolol in asthmatic patients: Interaction with terbutaline. Eur J Clin Pharmacol 1988;33(Suppl.):S25-S32.
13. 13. Karlson BW, Herlitz J, Hjalmarson Å, Impact of clinical trials on the use of beta-blockers after acute myocardial infarction and its relation to other risk indicators for death and 1-year mortality rate. Clin Cardiol 1994;17:311-316.
14. 14. McGovern PG, Herlitz J, Pankow JS, Karlsson T, Dellborg M, Shahar E, Luepker RV. Comparison of medical care and one- and 12-month mortality of hospitalized patients with acute myocardial infarction in Minneapolis-St Paul, Minnesota, United States of America and Göteborg, Sweden. Am J Cardiol 1997;80:557-562.
15. 15. Vlskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction. From randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-1332.
16. 16. Held P. Effects of beta blockers on ventricular dysfunction after myocardial infarction: Tolerability and survival effects. Am J Cardiol 1993;71:39C-44C.
17. 17. Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson Å. Effect of metoprolol on the prognosis among patients with suspected acute myocardial infarction and indirect signs of congestive heart failure. (A subgroup analysis of the Göteborg Metopolol trial). Am J Cardiol 1997;80(9B): 40J-44J.
18. 18. The Digitals Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
19. 19. Cooper HA, Dries DL, Domanski MJ. Diuretics and the risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1997;96(Suppl.):I-711 (abstract 3987).
20. 20. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
21. 21. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes. Ann Intern Med 1996;124:292-298.
22. 22. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991;67:1295-1297.
23. 23. Emanuelsson H, Karlsson BW, Herlitz J. Characteristics and prognosis of patients with acute myocardial infarction in relation to occurence of congestive heart failure. Eur Heart J 1994;15:761-768.